Krystal Biotech Stock Performance
| KRYS Stock | USD 160.05 1.55 0.96% |
The company secures a Beta (Market Risk) of -0.48, which conveys possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning Krystal Biotech are expected to decrease at a much lower rate. During the bear market, Krystal Biotech is likely to outperform the market. Krystal Biotech has an expected return of -0.0823%. Please make sure to verify Krystal Biotech treynor ratio, expected short fall, as well as the relationship between the Expected Short fall and day median price , to decide if Krystal Biotech performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Krystal Biotech has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of comparatively stable basic indicators, Krystal Biotech is not utilizing all of its potentials. The current stock price uproar, may contribute to short-horizon losses for the private investors. ...more
| Begin Period Cash Flow | 161.9 M |
Krystal |
Krystal Biotech Relative Risk vs. Return Landscape
If you would invest 17,084 in Krystal Biotech on March 5, 2024 and sell it today you would lose (1,079) from holding Krystal Biotech or give up 6.32% of portfolio value over 90 days. Krystal Biotech is currently does not generate positive expected returns and assumes 2.0773% risk (volatility on return distribution) over the 90 days horizon. In different words, 18% of stocks are less volatile than Krystal, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Krystal Biotech Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Krystal Biotech's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Krystal Biotech, and traders can use it to determine the average amount a Krystal Biotech's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0396
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | KRYS |
Estimated Market Risk
| 2.08 actual daily | 18 82% of assets are more volatile |
Expected Return
| -0.08 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.04 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Krystal Biotech is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Krystal Biotech by adding Krystal Biotech to a well-diversified portfolio.
Krystal Biotech Fundamentals Growth
Krystal Stock prices reflect investors' perceptions of the future prospects and financial health of Krystal Biotech, and Krystal Biotech fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Krystal Stock performance.
| Return On Equity | 0.0887 | ||||
| Return On Asset | -0.0497 | ||||
| Profit Margin | 0.60 % | ||||
| Operating Margin | 0.13 % | ||||
| Current Valuation | 4.04 B | ||||
| Shares Outstanding | 28.56 M | ||||
| Price To Earning | (6.36) X | ||||
| Price To Book | 5.59 X | ||||
| Price To Sales | 48.10 X | ||||
| Revenue | 50.7 M | ||||
| EBITDA | (92.22 M) | ||||
| Cash And Equivalents | 425.56 M | ||||
| Cash Per Share | 16.58 X | ||||
| Total Debt | 8.09 M | ||||
| Debt To Equity | 0.02 % | ||||
| Book Value Per Share | 28.02 X | ||||
| Cash Flow From Operations | (88.8 M) | ||||
| Earnings Per Share | 2.18 X | ||||
| Total Asset | 818.36 M | ||||
| Retained Earnings | (269.83 M) | ||||
| Current Asset | 2.05 M | ||||
| Current Liabilities | 40.74 K | ||||
About Krystal Biotech Performance
To evaluate Krystal Biotech Stock as a possible investment, you need to clearly understand its upside potential, downside risk, and overall future performance outlook. You may be satisfied when Krystal Biotech generates a 15% return over the last few months, but what if the market is generating 25% over the same period? In this case, it makes sense to compare Krystal Stock's performance with different market indexes, such as the Dow or NASDAQ Composite. These indexes can act as benchmarks that will help you to understand Krystal Biotech market performance in a much more refined way. The Macroaxis performance score is an integer between 0 and 100 that represents Krystal's market performance from a risk-adjusted return perspective. Generally speaking, the higher the score, the better is overall performance as compared to other investors. The score is normalized against the average investing universe (the best we can interpret from the data available). Within this methodology, scores of individual equity instruments will always be inferior to the scores of portfolios of equities as portfolios typically diversify a lot of unsystematic risks away. The formula to derive the Macroaxis score bases on multiple unequally-weighted factors. For more information, refer to our portfolio performance evaluation section.
Please also refer to our technical analysis and fundamental analysis pages.Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Krystal Biotech, Inc. was founded in 2015 and is headquartered in Pittsburgh, Pennsylvania. Krystal Biotech operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 119 people.Things to note about Krystal Biotech performance evaluation
Checking the ongoing alerts about Krystal Biotech for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Krystal Biotech help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Krystal Biotech generated a negative expected return over the last 90 days | |
| Krystal Biotech currently holds about 425.56 M in cash with (88.8 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 16.58. | |
| Krystal Biotech has a poor financial position based on the latest SEC disclosures | |
| Over 95.0% of the company shares are owned by institutional investors |
- Analyzing Krystal Biotech's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Krystal Biotech's stock is overvalued or undervalued compared to its peers.
- Examining Krystal Biotech's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Krystal Biotech's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Krystal Biotech's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Krystal Biotech's stock. These opinions can provide insight into Krystal Biotech's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Krystal Biotech. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in manufacturing. For more information on how to buy Krystal Stock please use our How to Invest in Krystal Biotech guide.You can also try the Content Syndication module to quickly integrate customizable finance content to your own investment portal.
Complementary Tools for Krystal Stock analysis
When running Krystal Biotech's price analysis, check to measure Krystal Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Krystal Biotech is operating at the current time. Most of Krystal Biotech's value examination focuses on studying past and present price action to predict the probability of Krystal Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Krystal Biotech's price. Additionally, you may evaluate how the addition of Krystal Biotech to your portfolios can decrease your overall portfolio volatility.
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Stocks Directory Find actively traded stocks across global markets | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes |
Is Krystal Biotech's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Krystal Biotech. If investors know Krystal will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Krystal Biotech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Krystal Biotech is measured differently than its book value, which is the value of Krystal that is recorded on the company's balance sheet. Investors also form their own opinion of Krystal Biotech's value that differs from its market value or its book value, called intrinsic value, which is Krystal Biotech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Krystal Biotech's market value can be influenced by many factors that don't directly affect Krystal Biotech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Krystal Biotech's value and its price as these two are different measures arrived at by different means. Investors typically determine if Krystal Biotech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Krystal Biotech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.